Adolor 8-K 2005
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) March 7, 2005
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code: (484) 595-1500
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 8.01. Other Events.
On March 7, 2005, Adolor Corporation (the Company) reported initial top-line results from two Phase 2 studies of Entereg (alvimopan), one evaluating alvimopan for the treatment of opioid-induced bowel dysfunction and the other investigating alvimopan in patients with chronic idiopathic constipation. The press release issued by the Company concerning the announcement is attached to this Report as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Dated: March 7, 2005